| 101 |
22836058 | The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis. | 2013 Mar 1 |
1 |
| 102 |
22863869 | Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. | 2013 Nov |
2 |
| 103 |
23263828 | A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. | 2013 Mar |
1 |
| 104 |
23275151 | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. | 2013 Apr |
3 |
| 105 |
23299493 | Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells. | 2013 Jan 8 |
2 |
| 106 |
23426424 | The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. | 2013 Mar |
2 |
| 107 |
23514287 | ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. | 2013 Mar 21 |
3 |
| 108 |
23523421 | Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. | 2013 Jul |
2 |
| 109 |
23549037 | ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. | 2013 Apr 30 |
1 |
| 110 |
23580445 | Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. | 2013 Jul |
1 |
| 111 |
23645290 | ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. | 2013 Jul |
2 |
| 112 |
23712330 | Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. | 2013 Aug |
3 |
| 113 |
23759026 | Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. | 2013 Jun 10 |
4 |
| 114 |
23773262 | 19q13-ERCC1 gene copy number increase in non--small-cell lung cancer. | 2013 Sep |
1 |
| 115 |
23790173 | Individualized treatment of NSCLC: from research to clinical practice. | 2013 |
1 |
| 116 |
23807173 | Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. | 2013 Jul 9 |
4 |
| 117 |
23817665 | β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. | 2013 Sep |
6 |
| 118 |
23856142 | [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs]. | 2013 Mar |
1 |
| 119 |
23962907 | ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. | 2013 Nov |
3 |
| 120 |
23975218 | [Muscle invasive bladder cancer after radical cystectomy. Prognostic factors of adjuvant chemotherapy]. | 2013 Sep |
1 |
| 121 |
24045016 | Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. | 2013 Nov |
1 |
| 122 |
24064970 | ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. | 2013 Oct 15 |
2 |
| 123 |
24083589 | Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer. | 2013 Nov |
1 |
| 124 |
24088734 | Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. | 2013 Dec 1 |
1 |
| 125 |
25806229 | Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). | 2013 Jun |
1 |
| 126 |
21553054 | Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. | 2012 Jan |
1 |
| 127 |
21676483 | Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. | 2012 Jan |
1 |
| 128 |
21996734 | Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. | 2012 May 10 |
8 |
| 129 |
22031231 | Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. | 2012 Jan |
4 |
| 130 |
22102173 | A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. | 2012 Feb |
3 |
| 131 |
22159227 | Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. | 2012 Feb |
1 |
| 132 |
22266184 | Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. | 2012 Aug 28 |
1 |
| 133 |
22266871 | Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. | 2012 Nov 1 |
4 |
| 134 |
22269178 | Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. | 2012 Sep |
1 |
| 135 |
22284908 | DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. | 2012 Apr 1 |
2 |
| 136 |
22344449 | ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications. | 2012 Jun |
5 |
| 137 |
22425915 | ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. | 2012 Apr |
1 |
| 138 |
22571922 | Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. | 2012 Oct |
4 |
| 139 |
22616552 | ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. | 2012 May 22 |
2 |
| 140 |
22960937 | A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. | 2012 Nov |
1 |
| 141 |
23098477 | Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. | 2012 |
4 |
| 142 |
23102199 | [Importance of expression of DNA repair proteins in non-small-cell lung cancer]. | 2012 |
1 |
| 143 |
23147544 | RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. | 2012 |
2 |
| 144 |
23171216 | Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. | 2012 Nov 21 |
2 |
| 145 |
23259415 | ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. | 2012 Dec 23 |
3 |
| 146 |
20605357 | Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? | 2011 Apr 1 |
1 |
| 147 |
20627363 | Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. | 2011 Feb |
1 |
| 148 |
20801905 | ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. | 2011 Mar |
3 |
| 149 |
21076943 | Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. | 2011 Apr |
7 |
| 150 |
21093896 | ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. | 2011 Feb |
2 |